170 related articles for article (PubMed ID: 34845439)
1. Tacrolimus as Single-Agent Immunotherapy and Minimal Manifestation Status in Nonthymoma Myasthenia Gravis.
Duan W; Peng Y; Jin W; Ouyang S; Yang H
J Immunol Res; 2021; 2021():9138548. PubMed ID: 34845439
[TBL] [Abstract][Full Text] [Related]
2. Adequate tacrolimus concentration for myasthenia gravis treatment.
Kanai T; Uzawa A; Kawaguchi N; Himuro K; Oda F; Ozawa Y; Kuwabara S
Eur J Neurol; 2017 Feb; 24(2):270-275. PubMed ID: 28102047
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis.
Wang L; Xi J; Zhang S; Wu H; Zhou L; Lu J; Zhang T; Zhao C
J Clin Neurosci; 2019 May; 63():160-167. PubMed ID: 30827886
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting outcome in ocular myasthenia gravis.
Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis.
Itani K; Nakamura M; Wate R; Kaneko S; Fujita K; Iida S; Morise S; Murakami A; Kunieda T; Takenouchi N; Yakushiji Y; Kusaka H
Neuromuscul Disord; 2021 Jun; 31(6):512-518. PubMed ID: 33903022
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis.
Kim YH; Shin HY; Kim SM
Yonsei Med J; 2019 Jul; 60(7):633-639. PubMed ID: 31250577
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy choice and maintenance for generalized myasthenia gravis in China.
Zhang C; Bu B; Yang H; Wang L; Liu W; Duan RS; Zhang M; Zeng P; Du C; Yang L; Shi FD
CNS Neurosci Ther; 2020 Dec; 26(12):1241-1254. PubMed ID: 33103369
[TBL] [Abstract][Full Text] [Related]
9. [Successful treatment by tacrolimus in two patients with Osserman's grade III intractable myasthenia gravis and elderly IIb].
Iwamoto T; Ioka M; Naito Y; Kagawa Y; Kuzuhara S; Kojima M
Yakugaku Zasshi; 2004 Apr; 124(4):237-41. PubMed ID: 15067188
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic efficacy and safety of tacrolimus for intractable myasthenia gravis: a report of 36 patients].
Feng HY; Liu WB; Qiu L; Huang X; Huang RX
Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(45):3190-2. PubMed ID: 22333101
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic and Immunoregulatory Effects of Tacrolimus in Patients with Refractory Generalized Myasthenia Gravis.
Wu H; Wang Z; Xi J; Liu J; Yan C; Song J; Wang L; Jing S; Wang Y; Zhao C
Eur Neurol; 2020; 83(5):500-507. PubMed ID: 32932253
[TBL] [Abstract][Full Text] [Related]
12. Clinical features, treatment and prognosis of MuSK antibody-associated myasthenia gravis in Northwest China: a single-centre retrospective cohort study.
Zhao S; Zhang K; Ren K; Lu J; Ma C; Zhao C; Li Z; Guo J
BMC Neurol; 2021 Nov; 21(1):428. PubMed ID: 34732168
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis.
Wang L; Zhang S; Xi J; Li W; Zhou L; Lu J; Lu J; Zhang T; Zhao C
J Neurol; 2017 Nov; 264(11):2191-2200. PubMed ID: 28921038
[TBL] [Abstract][Full Text] [Related]
14. A 5-Year Follow-Up of Triple-Seronegative Myasthenia Gravis Successfully Treated with Tacrolimus Therapy.
Tozawa T; Nishimura A; Ueno T; Kaneda D; Miyanomae Y; Chiyonobu T; Morimoto M; Hosoi H
Neuropediatrics; 2018 Jun; 49(3):200-203. PubMed ID: 29301152
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and side effects of low-dose tacrolimus for the treatment of Myasthenia Gravis.
Tao X; Wang W; Jing F; Wang Z; Chen Y; Wei D; Huang X
Neurol Sci; 2017 Feb; 38(2):325-330. PubMed ID: 27873026
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis.
Zhao LN; Liang Y; Fang XJ; Liu XM; Jiang QL; Wang SS; She SF; Cao M
Clin Neurol Neurosurg; 2018 Oct; 173():70-76. PubMed ID: 30092406
[TBL] [Abstract][Full Text] [Related]
17. Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome.
Kojima Y; Uzawa A; Ozawa Y; Yasuda M; Onishi Y; Akamine H; Kawaguchi N; Himuro K; Noto YI; Mizuno T; Kuwabara S
J Neurol Neurosurg Psychiatry; 2021 Sep; 92(9):963-968. PubMed ID: 33766920
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus.
Nagaishi A; Yukitake M; Kuroda Y
Intern Med; 2008; 47(8):731-6. PubMed ID: 18421189
[TBL] [Abstract][Full Text] [Related]
19. [A child with generalized myasthenia gravis successfully treated with tacrolimus].
Goto T; Mori M; Yamagata T; Mizuguchi M; Momoi MY
No To Hattatsu; 2007 Jul; 39(4):300-3. PubMed ID: 17633089
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients.
Li Y; Guptill JT; Russo MA; Massey JM; Juel VC; Hobson-Webb LD; Howard JF; Chopra M; Liu W; Yi JS
Exp Neurol; 2019 Feb; 312():43-50. PubMed ID: 30472069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
